Systemic therapies in metastatic pancreatic neuroendocrine neoplasms (PNENs): is there a right sequence? A case report and review of the literature.
Keywords:
PNENs, everolimus, temozolomide, chemotherapyAbstract
Management of pancreatic neuroendocrine neoplasms (PNENs) is very complex and heterogenous; therefore the right therapeutic strategy closely depends on a multidisciplinary approach. We report a case of 35-years-old man with advanced pancreatic neuroendocrine tumours (PNET). At beginning individual specialists planned earliest treatments. After disease progression the clinical strategy was handled within a multidisciplinary team and the patient received several therapies thanks to integration of team expertise. The patient died after 7 year from the diagnosis.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.